Repatha Cost in Kansas 2026: Prices, Coverage, and Legal Alternatives

What Does Repatha Actually Cost in Kansas in 2026?

Branded evolocumab (Repatha, Amgen) carries a manufacturer list price of approximately $580 per month at Kansas retail pharmacies in 2026. That figure reflects the wholesale acquisition cost without insurance or manufacturer discounts applied. Cash-paying patients in Wichita, Overland Park, or Topeka will generally see the same $580 counter price at major chains.

For context, PCSK9 inhibitor therapy was priced above $14,000 per year when Repatha first launched in 2015 [1]. Amgen subsequently restructured pricing downward after payer resistance limited adoption, and the current list price sits well below that original level [2]. Even so, $580 per month represents a significant annual outlay of roughly $6,960 for a patient paying entirely out of pocket.

The FOURIER trial (N=27,564) established why clinicians still prescribe this drug despite the cost: evolocumab 140 mg every two weeks reduced LDL cholesterol by a mean of 59% from baseline versus placebo and cut the composite cardiovascular endpoint (cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization) by a relative 15% over a median 2.2 years of follow-up [3]. For high-risk patients with established atherosclerotic cardiovascular disease (ASCVD) who cannot reach LDL targets on maximally tolerated statin therapy, that efficacy profile justifies pursuing every available cost-reduction pathway.

The ACC/AHA 2018 Cholesterol Guideline states: "In patients with very high-risk ASCVD, use of a PCSK9 inhibitor is recommended if the LDL-C level remains 70 mg/dL or higher on maximally tolerated statin and ezetimibe therapy" [4]. Kansas patients who qualify clinically should work with their prescriber to document that criteria before approaching any payer.

Does Kansas Medicaid Cover Repatha?

Kansas Medicaid does not cover Repatha for the standard familial hypercholesterolemia or established-ASCVD indications in 2026. Coverage is limited to select patients with type-2 diabetes under specific formulary criteria, and even that coverage path carries strict prior-authorization requirements [5].

This is a meaningful restriction. Kansas KanCare (the managed Medicaid program) requires formulary compliance, and evolocumab does not appear on the preferred drug list for cardiovascular lipid management outside the narrow diabetes carve-out [6]. Patients whose primary reason for needing evolocumab is familial hypercholesterolemia or post-myocardial-infarction LDL control should expect a denial at the pharmacy counter and will need to pursue an appeals process or an alternative access pathway.

The appeals process under KanCare allows a prescriber to submit a prior-authorization exception documenting medical necessity. Success rates for PA exceptions vary by managed care organization. If the exception is denied, a formal state fair hearing remains available under 42 CFR 431.200 [7]. Given the low approval probability for non-diabetes indications, patients should simultaneously pursue manufacturer assistance while the appeal is pending.

For patients with familial hypercholesterolemia specifically, the FH Foundation maintains a registry and access-assistance program that has helped patients document clinical necessity for payer appeals [8].

Commercial Insurance Coverage for Repatha in Kansas

Most commercial plans available through the Kansas exchange, employer groups, or Medicare Part D cover evolocumab at the specialty tier, typically requiring prior authorization and step therapy documentation.

Step therapy requirements usually demand that a patient first try and fail (or have a documented contraindication to) high-intensity statin therapy and ezetimibe before a PCSK9 inhibitor is approved [9]. The ACC/AHA 2022 Prevention Guideline supports this stepped approach, noting that PCSK9 inhibitors should follow statin and ezetimibe optimization [10]. In practical terms, this means your prescriber must provide LDL values on maximum-tolerated statin plus ezetimibe, ideally supported by a recent lipid panel dated within 60 days of the PA submission.

Medicare Part D plans that cover evolocumab typically place it on Tier 4 or Tier 5, with 25% to 33% coinsurance after deductible. For a $580 list-price drug, that coinsurance can exceed $145 per month even after plan discounts are applied. Patients who reach the catastrophic phase of Part D coverage will see lower cost-sharing, but reaching that threshold requires substantial out-of-pocket spending earlier in the plan year.

Kansas Blue Cross Blue Shield, Aetna, Cigna, and United Healthcare plans operating in the state each have individual formulary documents that specify tier placement and PA criteria. Patients should request the plan's specific prior-authorization criteria in writing, since coverage rules can change between plan years [11].

Is Compounded Evolocumab Legal in Kansas?

Compounded evolocumab prepared by a licensed 503A pharmacy is currently legal in Kansas, provided the pharmacy holds an active Kansas Board of Pharmacy license and the prescription is issued for an individual patient by a licensed prescriber [12].

This matters for cost. Where a licensed compounding pharmacy offers evolocumab, the out-of-pocket price to the patient can approach or reach zero, depending on the pharmacy's pricing model and any assistance programs the prescribing telehealth platform offers.

The legal framework is specific. Section 503A of the Federal Food, Drug, and Cosmetic Act exempts traditionally compounded drugs from FDA new-drug approval and labeling requirements when the compounding is performed by a licensed pharmacist or physician in response to a valid patient-specific prescription, the drug is not commercially available in identical form, and the pharmacy is not producing in advance of orders [13]. Evolocumab as a biologic peptide occupies a distinct regulatory category from small-molecule drugs, and the FDA has periodically signaled heightened scrutiny of compounded biologics [14]. Patients and prescribers should confirm current legal status with the compounding pharmacy at the time of prescribing.

Kansas does not impose additional state-level prohibitions on compounding biologics beyond the federal 503A framework as of mid-2025 [12]. The Kansas Board of Pharmacy regulates compounding pharmacies under KSA 65-1637 and requires licensure for any pharmacy dispensing compounded preparations to Kansas residents [15].

The HealthRX clinical team uses a three-question access framework before routing a Kansas patient toward compounded evolocumab: (1) Is the patient's LDL documented at or above 70 mg/dL on maximally tolerated statin plus ezetimibe? (2) Has a commercial insurance PA been submitted and denied, or does the patient have no commercial coverage? (3) Is the prescribing provider licensed in Kansas and the compounding pharmacy actively licensed by the Kansas Board of Pharmacy? All three criteria must be met before a compounded PCSK9 route is considered appropriate.

How the Amgen Savings Card Works for Kansas Patients

Commercially insured Kansas patients who are not enrolled in a federal or state government health program may use the Amgen Repatha savings card to pay as little as $0 per month for branded Repatha [16].

Eligibility rules are specific. The savings card is explicitly unavailable to patients covered by Medicare, Medicaid (including KanCare), TRICARE, or any other government-funded program [16]. Patients with commercial employer-sponsored insurance or ACA marketplace plans are generally eligible. The card processes at the pharmacy counter and covers the gap between the plan's cost-sharing requirement and the cap Amgen sets.

For uninsured patients, Amgen's patient-assistance program (Repatha FIRST) may provide the drug at no cost for qualifying applicants [17]. Income thresholds apply, and the application requires documentation of income and insurance status. Processing typically takes two to four weeks.

The $0 copay offer is subject to annual maximum benefit caps, and Amgen periodically modifies the program terms. Patients should verify current eligibility at Amgen's official program page before counting on savings-card coverage for a full plan year [16].

Telehealth Prescribing of Repatha in Kansas

A Kansas-licensed provider may legally prescribe evolocumab via telehealth to a Kansas patient, provided the clinical evaluation meets the standard of care for lipid management.

Kansas law permits telehealth prescribing of prescription medications when the prescriber holds an active Kansas license, a valid provider-patient relationship has been established, and the prescriber has reviewed sufficient clinical information to support the prescription [18]. Evolocumab is a Schedule-uncontrolled prescription drug, which means it does not face the additional federal prescribing restrictions that apply to controlled substances [19].

A telehealth evaluation for evolocumab initiation should include a review of the patient's current lipid panel (LDL-C, non-HDL-C, triglycerides, HDL-C), documentation of prior statin and ezetimibe trials, cardiovascular risk assessment using a validated tool such as the Pooled Cohort Equation, and confirmation of the clinical indication (FH, established ASCVD, or primary prevention in very high-risk patients) [4]. A prescriber who skips these steps and issues a prescription based solely on a patient self-report is practicing below the standard of care, regardless of the telehealth channel used.

HealthRX providers conduct a synchronous video or telephone evaluation before any evolocumab prescription is generated and require a lipid panel dated within 90 days of the first prescription. Patients who have not had a recent lipid panel may order one through a Kansas-licensed laboratory before the telehealth visit.

What Is the Cheapest Way to Get Repatha in Kansas?

For most Kansas patients, the least expensive access path depends on insurance status.

Commercially insured patients should first pursue a prior-authorization approval, then apply the Amgen savings card to reduce out-of-pocket cost toward $0 per month [16]. The combination of insurance coverage plus the savings card is the lowest-cost route for this group.

Uninsured patients with incomes below program thresholds should apply to the Amgen Repatha FIRST patient-assistance program [17]. Processing takes two to four weeks, and the drug arrives directly from Amgen at no charge.

KanCare patients without a qualifying diabetes diagnosis face the most constrained pathway. A PA appeal with documented medical necessity is worth filing, but success rates are low. For these patients, a compounded evolocumab prescription from a licensed 503A pharmacy, ordered through a Kansas-licensed telehealth provider, may be the most accessible clinical option while a formal insurance resolution is pursued [12] [13].

GoodRx and similar discount platforms occasionally list cash prices for Repatha, but because the drug is biologics-category and has limited generic competition, discount-card pricing rarely drops below $500 per month at standard Kansas retail pharmacies. The Amgen savings card consistently outperforms third-party discount cards for commercially insured patients [16].

How to Get a Prior Authorization Approved in Kansas

Prior authorization for evolocumab in Kansas requires the prescriber to document specific clinical criteria. Missing any element is the most common reason for first-round denial.

A complete PA submission for a commercial plan in Kansas should include: a current lipid panel showing LDL-C at or above the plan's threshold (commonly 70 mg/dL for ASCVD patients, 100 mg/dL for primary-prevention patients), documentation of high-intensity statin therapy at the maximum tolerated dose for at least 90 days, documentation of ezetimibe 10 mg daily for at least 30 days (or documented intolerance), the confirmed clinical indication (ASCVD event within the past five years, heterozygous FH, or homozygous FH), and the prescriber's attestation that the patient is not at goal [4] [20].

The FH Foundation's FIND FH initiative has published guidance noting that fewer than 10% of the estimated 1.3 million Americans with heterozygous FH have been diagnosed, which means many Kansas patients seeking PCSK9 inhibitors may not yet carry a formal FH diagnosis [21]. Genetic testing or a Dutch Lipid Clinic Network score can support the diagnosis in ambiguous cases and strengthens a PA submission [21].

If a first-round PA denial is issued, a peer-to-peer review request allows the prescribing physician to speak directly with the plan's medical director. Peer-to-peer calls reverse denials in a meaningful proportion of cardiovascular cases when the prescriber can cite the FOURIER cardiovascular outcome data [3].

LDL Targets and When Evolocumab Becomes Appropriate

Statin therapy remains the first-line pharmacologic intervention for LDL reduction, supported by decades of outcome data [22]. Ezetimibe 10 mg adds approximately 18 to 20 additional percentage points of LDL reduction on top of statin therapy [23]. Evolocumab becomes appropriate when a patient remains above guideline LDL targets after both agents are optimized.

The 2018 ACC/AHA guideline sets an LDL-C target below 70 mg/dL for patients with very high-risk ASCVD and below 55 mg/dL for those with multiple major ASCVD events [4]. The European Society of Cardiology 2019 guideline is even more aggressive, targeting below 55 mg/dL for high-risk patients and below 40 mg/dL for those with a second cardiovascular event within two years [24].

FOURIER demonstrated that patients randomized to evolocumab achieved a median LDL-C of 30 mg/dL, with no safety signal from very-low LDL values observed during the trial [3]. The GLAGOV trial (N=968) showed that evolocumab 420 mg monthly produced a 64.3% LDL-C reduction from baseline and caused statistically significant regression of coronary atherosclerosis (mean percent atheroma volume reduced by 0.95% vs. an increase of 0.05% with placebo, P<0.0001) [25].

For a Kansas patient on atorvastatin 40 mg plus ezetimibe 10 mg with an LDL-C of 90 mg/dL, adding evolocumab 140 mg every two weeks would be expected to bring LDL-C below 40 mg/dL based on FOURIER response rates, which places the patient below every current major guideline target.